200 related articles for article (PubMed ID: 17324140)
1. Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles.
Okuyama CE; Mendes GD; Faro R; Rezende VM; Lagos RM; Astigarraga RE; Antunes E; De Nucci G
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):290-5. PubMed ID: 17324140
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the inhibitory effect of N(G)-nitro-L-arginine methyl ester on the antihypertensive effect of the angiotensin AT1 receptor antagonist, GR138950.
Anderson IK; Drew GM
Br J Pharmacol; 1997 Dec; 122(7):1385-94. PubMed ID: 9421286
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol.
Bendtsen F; Henriksen JH
J Hum Hypertens; 1989 Jun; 3 Suppl 1():139-45. PubMed ID: 2550636
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous quantification of enalapril and enalaprilat in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study.
Lu S; Jiang K; Qin F; Lu X; Li F
J Pharm Biomed Anal; 2009 Jan; 49(1):163-7. PubMed ID: 19046843
[TBL] [Abstract][Full Text] [Related]
5. Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in rats.
García-Estañ J; Ortiz MC; O'Valle F; Alcaraz A; Navarro EG; Vargas F; Evangelista S; Atucha NM
Clin Sci (Lond); 2006 Feb; 110(2):227-33. PubMed ID: 16197366
[TBL] [Abstract][Full Text] [Related]
6. Protective effects of ACE inhibitors on vascular endothelial dysfunction induced by exogenous advanced oxidation protein products in rats.
Chen SX; Song T; Zhou SH; Liu YH; Wu SJ; Liu LY
Eur J Pharmacol; 2008 Apr; 584(2-3):368-75. PubMed ID: 18334254
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers.
Marzo A; Dal Bo L; Mazzucchelli P; Monti NC; Crivelli F; Ismaili S; Giusti A; Uhr MR
Arzneimittelforschung; 2002; 52(4):233-42. PubMed ID: 12040965
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses.
Gardner SY; Atkins CE; Sams RA; Schwabenton AB; Papich MG
J Vet Intern Med; 2004; 18(2):231-7. PubMed ID: 15058776
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine.
McLean AJ; Drummer OH; Smith HJ; Froomes P; McNeil JJ
J Hum Hypertens; 1989 Jun; 3 Suppl 1():147-51. PubMed ID: 2550637
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays.
Arafat T; Awad R; Hamad M; Azzam R; Al-Nasan A; Jehanli A; Matalka K
J Clin Pharm Ther; 2005 Aug; 30(4):319-28. PubMed ID: 15985045
[TBL] [Abstract][Full Text] [Related]
11. Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats.
Sacco G; Evangelista S; Criscuoli M; Goso C; Bigioni M; Binaschi M; Manzini S; Maggi CA
Eur J Pharmacol; 2005 Mar; 511(2-3):167-74. PubMed ID: 15792785
[TBL] [Abstract][Full Text] [Related]
12. Modulated hemodynamic response to clonidine in bile duct-ligated rats: the role of nitric oxide.
Tavakoli S; Hajrasouliha AR; Jabehdar-Maralani P; Ebrahimi F; Sadeghipour H; Dehghani M; Shafaroodi H; Dehpour AR
Eur J Pharmacol; 2006 Aug; 542(1-3):148-53. PubMed ID: 16824510
[TBL] [Abstract][Full Text] [Related]
13. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses.
Gómez-Díez M; Muñoz A; Caballero JM; Riber C; Castejón F; Serrano-Rodríguez JM
Res Vet Sci; 2014 Aug; 97(1):105-10. PubMed ID: 24972864
[TBL] [Abstract][Full Text] [Related]
15. Hepatic morphological alterations, glycogen content and cytochrome P450 activities in rats treated chronically with N(omega)-nitro-L-arginine methyl ester (L-NAME).
Tarsitano CA; Paffaro VA; Pauli JR; da Silva GH; Saad MJ; Salgado I; da Cruz-Höfling MA; Hyslop S
Cell Tissue Res; 2007 Jul; 329(1):45-58. PubMed ID: 17436021
[TBL] [Abstract][Full Text] [Related]
16. Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing.
Edeki T; Johnston A; Li Kam Wa E; Turner P
Int J Clin Pharmacol Ther; 1994 Mar; 32(3):142-6. PubMed ID: 8205376
[TBL] [Abstract][Full Text] [Related]
17. Lateral hypothalamus lesions influences water and salt intake, and sodium and urine excretion, and arterial blood pressure induced by L-NAME and FK 409 injections into median preoptic nucleus in conscious rats.
Abrão Saad W; Guarda IF; Camargo LA; Garcia G; Gutierrez LI; Abrão Saad W; Simões S; Saad Guarda R
Life Sci; 2004 Jun; 75(6):685-97. PubMed ID: 15172178
[TBL] [Abstract][Full Text] [Related]
18. Effect of acute inhibition of nitric oxide synthesis by L-NAME on cardiovascular responses following peripheral autonomic blockade in rabbits.
Eldesoky ES
Fundam Clin Pharmacol; 2006 Jun; 20(3):239-45. PubMed ID: 16671958
[TBL] [Abstract][Full Text] [Related]
19. Vasopressin response and shunting modulation in cirrhotic rats by chronic nitric oxide inhibition.
Huang HC; Wang SS; Lee FY; Chang CC; Chang FY; Lin HC; Hou MC; Lee SD
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e265-9. PubMed ID: 17764528
[TBL] [Abstract][Full Text] [Related]
20. Hepatic portal venous delivery of a nitric oxide synthase inhibitor enhances net hepatic glucose uptake.
Moore MC; Dicostanzo CA; Smith MS; Farmer B; Rodewald TD; Neal DW; Williams PE; Cherrington AD
Am J Physiol Endocrinol Metab; 2008 Apr; 294(4):E768-77. PubMed ID: 18212022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
